| |
The importance, danger and costs of tuberculosis in the 21st century
cannot be understated or underestimated. Though nearly extinct in the
20th century, Over 1.6 billion people worldwide suffer from
tuberculosis, and it is now presenting a major crisis in public health
circles.
In addition to the basic pathology and complications of tuberculosis,
there are primarily three focal points for the development of strategy
in this area: potential market, epidemiology (tuberculosis patient
trends) and technology. |
|
| |
RFID (Radio Frequency IDentification) technologies are dramatically
changing many industries, but as detailed in Kalorama's market research
report RFID Opportunities in Healthcare in the U.S., the greatest market
for RFID is in healthcare. Hospitals, pharmaceutical companies, nursing
homes, and other healthcare entities will benefit from using the
technologies to keep track of inventories and patients. |
|
| |
Although Asia Pacific was the smallest healthcare market as of 2006,
out of the three major geographic regions (US, Europe, and Asia
Pacific), continued growth makes it an important ancillary market for
makers of medical devices. |
|
| |
This study U.S. Market for Home Care Products, 5th Edition
represents the fifth time Kalorama Information has investigated this
growing market over the past 12 years.
The U.S. market for home care products and equipment continues to
post steady gains, primarily as a result of the aging population and
increasing shifts of chronic care patients from hospitals to home.
Serious market watchers will want to keep aware of trends in this
industry, movers and shakers as well as market data. |
|
| |
Many in the clinical and manufacturing community have their eyes on
the Physician Office Laboratory (POL) as an outlet both to improve
patient compliance and outcomes and to open new market opportunities.
Studies are emerging on the clinical outcomes and cost-benefit of
nearer-the-patient testing, but little certain is known about POLs as a
distribution channel for diagnostics products. |
|
| |
Molecular imaging maps the locations of specific molecules and
biomaterials within living tissue. As such, it has the potential to
diagnose a disease, to monitor the course of that disease, and possibly
facilitate treatment. Molecular imaging has developed into a promising
new strategy for the diagnosis, evaluation and treatment of disease. |
|
| |
This series provides total coverage of the Anti-Infectives market, a
market that is changing due to product development resistance issues and
in some cases, generic competition.
Antifungals
Antibacterials
Antivirals
As part of its comprehensive coverage, each report includes:
Epidemiology including Incidence Statistics for each type of
infection.
Current Market Size and Revenue Forecasts for each market segment to
assist with long term planning.
Discussion of Competitive Products in the market and new products in
the delivery pipeline.
Coverage of Generic Threats for affected major products.
Round-Up of the Key Players in each area of anti-infectives.
Over 195 Tables and Figures for easy access to information and decision
support tools, internal emails, memos and presentations.
Discussion of Unique Issues and Emerging Trends for each antibiotic
area.
Market Share of Leading Competitors for each area.
U.S., Europe, Japan and Rest of World market data.
Product managers, marketing directors, business development executives
in the pharmaceutical industry and financial and consulting company
executives who invest in or serve this industry are among those who will
find this report a useful resource. |
|
| |
This third volume of Kalorama Information’s World Market for Anti-Infectives
series, the 2nd. Edition focuses on three general product segments of
antiviral treatment:
Nucleoside Analogs
Protease Inhibitors
Other Misc. Antivirals
The report covers both currently marketed and late stage development
antiviral products in detail. For each segment, the report provides:
Revenue Data by Infection Type
An overview of products on the market
Review of products in the development pipeline
Market estimates and forecasts through 2011
Market segmentation by geographic region
Market share of leading suppliers
Market share of leading products
The report also includes statistical (epidemiologic and demographic)
information for viral infections by type worldwide, with special
emphasis on the United States and describes the major clinical,
business, and regulatory trends shaping the global and domestic markets.
The information for this report was gathered using both primary and
secondary research including comprehensive research of secondary sources
such as company literature, databases, investment reports, and medical
and business journals. In addition, Kalorama Information conducted
interviews with key industry officials, consultants, health care
providers, and government personnel. These sources were the primary
basis in gathering information specifically relating to revenue and
market share data presented in this report. Specific interviews with
pharmaceutical company representatives included marketing directors,
division managers, and product representatives. |
|
| |
Cancer is the second most common cause of death in the
industrialized world. At this time, treatment for cancer focuses on some
combination of surgery, radiation, and chemotherapy.
But over the next five years, treatment is going to dramatically
change. as detailed in the report Monoclonal Antibodies, Vaccines and
Other Immunologic Cancer Treatments: World Market from Kalorama
Information. One of the most promising new approaches in modern cancer
treatment is immunotherapy, the development of methods to augment and
enhance the body’s natural tendency to defend itself against malignant
tumors without damaging healthy tissue. Immunological and biotherapy
treatments which target therapy are a fraction of total cancer treatment
revenues at the current time, but will soon make up the lion’s share of
the total cancer therapy market. |
|
 |
New biological treatments are being developed at a record place, but
their potential could be compromised by significant obstacles to
delivery of these drugs into the body. Pharmaceutical delivery is now
nearly as important as product. New systems are being developed, and
Kalorama's Drug Delivery Markets Series covers these new systems. |
|
| |
Part of a three volume series.
Over one billion people suffer from fungal infections worldwide.
Although athlete's foot, dandruff, vaginal yeast infection and fungal
nail are the most common, there has been a steady increase in the
incidence of more serious infections. This is partially due to the
widespread use of antibiotics, which eliminate or decrease fungi-killing
bacteria. Another has been the increased number of individuals with
reduced immune responses caused by AIDS or the effects of chemotherapy.
These are part of the factors that have lead to nearly 6-billion dollar
antifungal drug industry. |
|
| |
This report includes all four volumes of Kalorama's 2nd edition of
its Drug Delivery Markets series, covering all major types, including:
Oral Delivery
Implantable/Injectable
Pulmonary
Transdermal/Transmucosal |
|
| |
Since the advent of LASIK nearly two decades ago, refractive vision
correction remains a vibrant market impacted by technology. Kalorama's
market analysis takes a look at the entire market for non-disease eye
treatment procedures. Complete coverage of the vision correction market,
including the correction of conditions such as myopia (nearsightedness),
presbyobia (an inibility to focus), astigmatism and hyperopia or
far-sightedness. |
|
| |
Smoking cessation is an increasingly important area of focus for
pharmaceutical companies, healthcare entities and governments. There are
1.4 billion smokers in the world, and with smoking is a known cause of
heart disease, lung cancer, respiratory infections and many other
diseases. This has created a large market for smoking cessation aids. |
|
| |
The market for diabetes-related products is huge and continuing to
grow. However, it is not the same market as it was just 3 years ago. New
trends in care, new products (both therapeutic and diagnostic), new
approaches to long-term complications, and changing public health
priorities and geographic variations are shifting the sands of
opportunities in diabetes care. |
|
| |
Contrast agents and radiopharmaceuticals have revolutionized in vivo
imaging. Technical developments in contrast media and imaging techniques
is combining with the trends toward both the functional and molecular
understanding of disease to create a rapidly growing marketplace in
these agents. |
|
| |
The lungs are considered by many to be the best alternative for
drugs needing to bypass the gastrointestinal tract. With advancing
technology, the practice of utilizing the huge surface area of the lungs
to delivery drugs into the blood circulation has been slowly
transforming into reality. |
|
| |
Molecular diagnostics (also known as nucleic acid testing) has
emerged as a field that promises to renew technological progress in the
clinical laboratory and to vastly improve patient care. Although it has
been a slower than anticipated adoption in the clinical laboratory
setting, molecular diagnostics has begun to overcome the impediments of
incomplete genetic knowledge, the development of new technology
platforms, and the communication of their use and efficacy to lab
personnel and clinicians alike. |
|
| |
Few pharmaceutical markets will see the dramatic change that will
occur in cancer therapeutics over the next four years. More than $8
billion dollars worth of new products are expected in the next four
years, impacting the treatment of cancer in ways that product managers,
strategic planners, business development managers and marketing
executives will need to be aware of.
|
|
| |
Fueled by the promise of needle-free mechanisms for vaccine
distribution and other pharmaceutical uses, the implantable/injectable
drug delivery market is growing rapidly. The development of better
delivery systems in conjunction with the discovery of novel
pharmacological compounds will lead to continued growth. |
|
| |
In the next few years, U.S. hospitals, health systems and group
practices have earmarked billions for the purchase of technologies that
will help them improve efficiencies and reduce costs. Electronic Medical
Record (EMR) technology will certainly be among their purchases.
EMR has proven it can make healthcare workflow more efficient, reduce
costs, while at the same time improving the quality of patient care.
Given these undisputable benefits, the 1.2 billion-dollar market for EMR
is expected to grow nearly 400% in the next eight years, according to
Kalorama’s experts.
|
|
| |
Wireless technologies and healthcare are a perfect fit. The clinical
environment is a highly mobile one, and physicians, nurses and other
clinical operators have a real need for fast information and action.
With a record of successful implementations across aspects of healthcare
from patient care to sales, wireless technologies have moved from
conjecture to reality. Hospitals are dedicating large portions of
current and future budgets to IT development and wireless is likely to
be among their choices. Given these trends, Kalorama expects the 1.7
billion dollar wireless healthcare market to grow to four times its
current size by the end of the decade.
|
|
| |
Lateral flow tests, also known as immunochromatographic strip (ICS)
tests, offer dramatic benefits in the diagnostic process that point
towards a robust market. LF tests reduce the time spent waiting for test
results from hours to minutes, require less training for operators, and
reduce the cost of both device development and manufacturing.
|
|
| |
Molecular diagnostics has emerged as a field that promises to renew
technological progress in the clinical laboratory and to vastly improve
patient care. Although it has been a slower than anticipated adoption in
the clinical laboratory setting, molecular diagnostics (also called
nucleic acid testing) has begun to overcome the impediments of
incomplete genetic knowledge, the development of new technology
platforms, and the communication of their use and efficacy to lab
personnel and clinicians alike. |
|
| |
The current population of India is 1.065 billion, and with a growth
rate of 1.7%, India will surpass China to become the world’s largest
country around 2030. For diagnostic manufacturers, this enormous market
is just now being recognized as a high-growth area as the pace of
economic growth in India accelerates and modern laboratory practices
become established. |
|
| |
With a growing elderly population, premium pricing, and growing new
venues for sales, the kidney dialysis and dialysis equipment market
approaches $55 billion worldwide and is expected to grow. With those
revenues coming from just 1.6 million patients worldwide, kidney
dialysis and equipment is among the most lucrative markets in per-capita
terms. |
|
| |
What are the trends that are fueling a new boom in vaccine
production and sales? Why is an industry so commonly associated with
children finding an increasing marketplace among adult populations? What
makes this class of drugs likely to grow at a faster rate than other
pharmaceutical products? These are among the questions answered in
Kalorama’s in-depth report, Vaccines: The World Market. |
|
| |
The market for psychotherapeutics drugs is about to change
dramatically -- and serious pharmaceutical market watchers will want to
be prepared. Kalorama’s World Market for Psychotherapeutic Drugs is the
most exhaustive guide available to this booming market and the direction
it is headed in the next four years.
Psychotherapeutics treat conditions classified as abnormal behavior,
thoughts and feelings that persist for a determined amount of time
causing distress or emotional/physical impairment. Depression, anxiety,
psychosis, ADHD and nicotine and drug dependence are among the
conditions psychotherapeutics treat. Well-known brands such as Prozac™,
Zoloft™ and Ritalin ™ have made this a $37 billion market. And according
to Kalorama’s research, revenues from this area will grow more than 50%
by 2010. |
|
| |
The oral drug delivery market is the largest segment of the drug
delivery market, and there’s no sign that it is slowing down. With
pharmaceutical companies increasingly turning to drug delivery to extend
the revenue-earning lifetime of their biggest products, find a
convienient form and market acceptance of new biopharmaceuticals, and
tap into the growing elderly population that requires products with a
level of ease-of-use and cost benefit, it’s no surprise that the oral
delivery drug market is a $35 billion industry and expected to grow as
much as ten percent per year. |
|
| |
Since more than 11 million Americans report pain as a significant
disability, there’s no question that pain management is big business for
healthcare practitioners today, and one area that market watchers need
to understand. When viewed globally, there is a large underserved
population for pain management medications, which indicates growth in
what is now a 26 billion-dollar plus industry. |
|
| |
In the pharmaceutical industry, cell culture is a major foundation
of biopharmaceutical development, bioprocessing and manufacturing.
Biopharmaceutical products are developed from large, complex protein
molecules, which require equally complex manufacturing methods and an
array of analytical techniques. As growing cells for biopharmaceutical
production is slow, expensive and complicated, optimizing cell culture
development is of paramount concern to companies developing
biopharmaceuticals. |
|
| |
Personalized medicine, the use of therapies that are targeted to the
individual patient, is a reality today, thanks to a growing emphasis on
biomarker research. Biomarkers are anatomic, physiologic, biochemical or
molecular parameters that are associated with the presence and severity
of specific diseases and illnesses. Biomarkers promise a smoother
integration of diagnostics and therapeutics, and most importantly a
reduction in time and cost for Phase I and II clinical trials.
|
|
| |
Collectively, the techniques of photon-based experimental
manipulation and advanced optical imaging define the field of
biophotonics. There are several key areas that are associated with
biophotonics. All of these center on microscopy and related technology.
The reason that this is so is that biophotonics look at biological
functions at the cellular level, or even smaller. The only way that
these processes can be observed is via one or another form of
microscopy. |
|
| |
This report takes a bold look into the markets, technologies, and
trends in decentralized testing with a special focus on the economics of
rapid test use in critical care and emergency medicine. There is also an
emphasis on early disease detection via rapid test use in clinics and
public venues. The report is conservative in its predictions and offers
a calculated look into the future, based on events currently taking
place. |
|
| |
Protein biomarkers have become the hot application area for mass
spectrometry (MS) and other proteomics-related technologies in the last
few years. In the short term, this move towards biomarkers and clinical
proteomics research has happened mainly in the drug discovery and
development process. However, they also have broad abilities to generate
richer information about a disease state, drug response, and/ or the
relation between the two; which can be used for diagnostic, prognostic,
or various other purposes in the pharmaceutical, diagnostics, and
defense industries. |
|
| |
Propelled by advances in molecular biology, the cancer vaccine
industry is poised for unprecedented growth. This second edition of
Kalorama’s groundbreaking 2003 study completely updates the market data
and reviews the technological, clinical, and business trends that have
shaped and reshaped this emerging field. |
|
| |
Despite troublesome safety problems with past entrants into this
market, the veritable epidemic of overweight and obesity continues to
make this sector an extremely attractive target for pharmaceutical
developers. This new title provides a considered view of the market for
medical interventions in the battle against obesity, including U.S. and
worldwide market size and growth forecasts, competitive market share and
extensive pharmaceutical pipeline information. |
|
| |
With the incidence of cardiac disease on a constant growth curve, a
test modality that can provide specific, inexpensive screening tools for
cardiovascular disease (CVD) before the onset of symptoms, is like the
proverbial "license to print money," and a large menu of tests have been
developed, including serum lipids, hypercoagulation factors, enzyme and
protein markers, genetic makeup, and even tests for certain viral
infections.
|
|
| |
Ultrasound, also known as sonography, is not a new imaging
modality—having been around since the 1950s—but its application areas
have just recently begun to expand tremendously. These new clinical
applications, along with technological innovations in portability and
resolution and a very favorable risk profile, have made ultrasound
equipment a very robust market sector. |
|
| |
The orthopedic drug market is a highly competitive market and, in
some areas, the competitive environment is being shaped by increasing
levels of generic competition. Several large pharmaceutical companies
compete in the orthopedic drug market, including Abbott, Eli Lilly,
GlaxoSmithKline, Merck, Novartis, and Pfizer among others, and several
other suppliers, such as Serono, NovoNordisk, Amgen, and Genentech are
developing or offering products in more niche market areas. |
|
| |
The global market for prescription respiratory drugs encompasses a
wide variety of products that treat both common everyday respiratory
illnesses as well as serious chronic conditions such as COPD.
Technological developments and improved delivery methods have given many
health professionals a wider range of products to treat patients with
respiratory diseases and have expanded the market for respiratory
pharmaceuticals. |
|
| |
This report focuses on the applications of current and advanced
therapeutics to the treatment of psoriasis and psoriatic arthritis, the
options they present, and the progress that is being made in these
fields. The major market effects of new therapeutics, with the potential
of a breakthrough drug always a possibility, are expected to be seen
over the next ten years. |
|
| |
This report is focused on two expanding pharmaceutical outsourcing
markets, contract manufacturing and contract sales and marketing. Both
markets represent excellent post launch outsourcing opportunities for
companies competing in this fast growing pharmaceutical outsourcing
sector. |
|
| |
This comprehensive evaluation of the blood industry provides an
analysis of all the key market segments involved in this industry,
including blood products such as: Red Blood Cells (RBCs),
Immunoglobulins, Albumin, Other Plasma Products, Synthetic HBOC and PFC
Agents, Recombinant Factors |
|
| |
This volume of the Medical Imaging Markets series explores the world
of magnetic resonance imaging. This modality continues to generate
growth as applications expand and new "open" systems penetrate the
market. |
|
| |
The past 25 years have seen unprecedented advancements in the area
of women’s health. A number of events have helped to bring the concerns
of women’s health to the forefront of medicine but the most significant
was the women’s health movement, which increased attention to women’s
health issues and the shortcomings of traditional medical practice and
research.
|
|
| |
This report provides and in-depth analysis of the market for
prescription drugs used in the treatment of gastrointestinal (GI)
disorders, such as nausea and vomiting, heartburn, gastro-esophageal
reflux disease (GERD), ulcer, cancers of the GI tract (colorectal,
esophageal, and gastric), Crohn’s disease, ulcerative colitis, irritable
bowel syndrome (IBS), diverticular disease, constipation, celiac
disease, short bowel syndrome, diarrhea, intestinal obstruction, and
digestive enzyme disorders. |
|
| |
This complete re-evaluation of the Men’s Health market focuses on
the following prescription drug treatment segments: Men’s Cancer, Men’s
Sexual Dysfunction, Men’s Sexually Transmitted Diseases, Men’s Urinary
Conditions, Andropause |
|
| |
This second edition of Kalorama’s best-selling look at the clinical
contract research industry provides the key information competitors need
to navigate the complexities and costs of clinical research in the drug
development process. In addition to a comprehensive discussion of the
market and regulatory environment, the report details: |
|
| |
The strategic interplay of of HIV/AIDS diagnostics and therapeutics
is one of the most complex that the healthcare industry has ever seen.
In order to cope with the challenges and opportunities of HIV/AIDS,
companies must think on a global basis, and in addition to the basic
pathology and complications of HIV/AIDS, there are societal and ethical
pressures, geopolitical factors, and evolving marketplace disruptions.
|
|
| |
Ophthalmology is entering one of the most remarkable phases in
recent history of this industry; new technologies and treatment
modalities for both visual acuity and major eye diseases may
dramatically change the composition and competitive dynamics of this
market. As RK and LASIK changed the market a few years ago, even newer
competitive technologies are just now emerging. From the advent of
photodynamic therapy and new drug delivery techniques to revolutionary
surgical approaches to refractive vision correction, ophthalmology is
poised to see a plethora of new treatment options. |
|
| |
The major indications for critical care are discussed as well as the
range of pharmaceutical products used in the critical care environment.
The strategic market characteristics of the critical care
pharmaceuticals market are also discussed. The trends —-
cost-containment programs, restricted formulary acceptance, clinical
pharmacy, and the growth of the generic drug population —- as well as
their impacts on the clinical care pharmaceutical markets are discussed.
These are selected to assess the rationale for intentionally targeting
the critical care pharmaceuticals market in hospitals alone and as part
of an overall hospital pharmaceutical marketing strategy. They are
presented to provide the most informative picture of potential market in
this field. |
|
| |
The field for glucose testing devices is crowded; worldwide, more
than 50 companies market blood glucose monitors. The extraordinary
market growth fueled by the increasing numbers of diagnosed diabetics
continues to attract more entrants to the industry. Glucose self-testing
has, therefore, attracted a varied cast of players including: large
multinational companies such as Abbott Laboratories, Bayer Corp.,
LifeScan/Johnson & Johnson, and Roche Diagnostics; insulin pump
companies Medtronic/MiniMed, Disetronic; and Animas and smaller device
companies such as Home Diagnostics and Sontra Medical Inc.
|
|
| |
The reinvigorated market for medical imaging systems employing
x-rays has undoubtedly been propelled by the explosion of digital
technology. But also, the expanded role of imaging modalities in a whole
host of clinical applications from trauma to cancer to cardiology has
increased the profile of radiography while enabling computer
technologies expand the usefulness of traditional x-ray techniques. |
|
| |
The protein therapeutics sector is a story of triumphant science,
representing both life-saving treatments for millions and a
multi-billion dollar industry. This report details both the scientific
and business aspects of the protein therapeutics marketplace, including
market size and growth, competitive market share, geographical
segmentation, top products, and forecasts to 2010 for each of the
following individual product areas:
|
|
| |
The commercial world of medical sensors is vibrant and evolving
rapidly. Reports that are only a year or two old are already out-of-date
as new technologies make rapid penetration. This new edition attacks the
field from the point of view of current R&D, technology and innovation,
with an eye to potential markets and emerging technologies in clinical
medicine, remote and military applications, process and materials
quality control, environmental monitoring, and food and drug quality
control. |
|
| |
There are hundreds of drugs in Phase III clinical trials, of which
almost 200 of them may gain market approval from the FDA in the coming 5
years. Which drugs will make it and how these drugs impact existing
pharmaceutical markets in terms of overall size and competitive share is
one of the most difficult forecasting projects in market research.
|
|
|
|
| |
Adjunctive therapies are not only vital to the success of cancer
treatments, enhancing compliance and outcomes, but they are also a
dynamic area of research and development in a variety of disciplines
from drug delivery to biologics. It also happens to be the largest
portion of the overall cancer therapeutics market.
This report provides the reader with a comprehensive analysis of the
worldwide market for therapeutics to treat and manage symptoms in cancer
patients. Market information, including market size and growth, is
provided for 2003 to 2010 on various product subcategories
|
|
| |
The landscape of generic companies is changing: their relative might
in the industry is increasing and the product lines their offering are
growing in depth and breadth. Strong growth in the sector has come not
only from more aggressive tactics and better acceptance in the clinical
and consumer population, but by the loss of patent protection in the
past few years of some huge-name drugs, including Prozac, Zocor,
Prilosec, Prevacid, Sporanox, Evista, Flovent, Claritin, Allegra,
Diflucan, Zofran, Zoloft, and Pravachol.
|
|
| |
This report on the U.S. market for over-the-counter (OTC) pediatric
medications presents an in-depth analysis of the performance of
non-prescription pediatric drugs and other selected pediatric healthcare
products in the marketplace. The analysis captures the performance of
the market players, categories, and leading brands in terms of revenue
growth and volume growth in several categories of medication |
|
